# A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL

Source: https://onco.cc/trials/nct07609823/  
OnCo record `nct07609823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lacutoclax in chronic lymphocytic leukaemia, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.

## Summary

A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL is a phase 2 interventional study registered as NCT07609823 by Guangzhou Lupeng Pharmaceutical Company LTD., with 75 participants planned, started 2026-07-14 and due to reach its primary completion in 2028-03-30. Interventions recorded: Lacutoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07609823
- Phase: 2
- Setting: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Lacutoclax (LP-108) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07609823: https://clinicaltrials.gov/study/NCT07609823

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)

---
JSON: https://onco.cc/api/v1/entities/nct07609823.json